Novartis’ Beovu matched Regeneron’s Eylea in vision clarity scores for a blindness-causing eye disease, the Swiss drugmaker said, after early safety stumbles for the medicine in another condition caused disappointing early sales.
The U.S. Food and Drug Administration approved the expansion of Amgen’s Kyprolis (carfilzomib) U.S. prescribing information to include the product’s use in combination with Darzalex (daratumumab) plus dexamethasone (DKd) in two dosing regimens – once weekly and twice weekly – for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy.
During this webinar, learn more about benefits and risks of changing primary components during product development and how a design of experiments approach can be used to address issues and risks.
Eli Lilly and AbCellera dosed the first patients in a Phase I study of a potential antibody treatment for COVID-19.
A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences Inc. and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.
Merck’s Keytruda (pembrolizumab) received a rejection from the U.S. Food and Drug Administration for each of six supplemental Biologics License Applications to update the dosing frequency of the checkpoint inhibitor to include every-six-weeks administration.
Intent Solutions, an Atlanta-based company that provides technology to secure medications and track prescription adherence, is collaborating with AT&T to integrate LTE-M cellular technology into the new release of Intent’s tad dispensing system.
A panel of outside advisers to the U.S. Food and Drug Administration on Thursday voted against approving Purdue Pharma’s opioid painkiller over concerns of overdosing. The recommendation follows comments from the health regulator’s staff on Tuesday on likely errors in administering the experimental drug. The agency’s staff on Wednesday had also highlighted that a rival […]